State Biotech Policy

Mark Herzog, executive director of the Virginia Biotechnology Association recently discussed the success and challenges facing the burgeoning bioscience industry in his state.

The Maryland initiative’s 10-year plan helps build biotech access to funding

Derek Gregg discusses biotech in WV – major growth areas, outlook for the future, and upcoming plans for the BIO International Convention.

BIOtechNow’s Tracy Cooley discusses biotech in West Virginia – major growth areas, outlook for the future, and upcoming plans for the BIO International Convention – with Derek Gregg.

The Massachusetts Life Sciences Center, which is tasked with administering the $1 billion state's life sciences initiative, has awarded five loans to start up companies, totaling $3.75 million.

Budget victories will help biotechnology in the Commonwealth

The U.S. bioscience industry continued to score employment gains through 2008 - the first year of the recent economic downturn, according to a study released today by Battelle and the Biotechnology Industry Organization (BIO).

The following expresses the agricultural values of the Biotechnology Industry Organization, and its more than 1,000 member companies located across the United States and in 33 countries.

Biotechnology is all around us and is already a big part of our lives, providing breakthrough products and technologies to combat disease, reduce our environmental footprint, feed the hungry, and make useful products.

This report presents the estimates of the significant financial contributions of the biotechnology industry to the U.S. economy and to revenues collected by the federal, state and local governments.

Ohio is a national leader in terms of both bioscience employment and establishments. In fact the industry accounts for about 15 percent of the state’s total economic output.

January 31 2014
Dear Ms. Badrov:   The Biotechnology Industry Organization (BIO) and the Illinois Biotechnology Industry Organization (iBIO) appreciate this opportunity to comment on the Illinois Department of Healthcare and Family Services (the “Department”) proposed rule to amend 89 Ill. Adm. Code 140 regarding the 340B Drug Discount Program (the “Proposed Rule”).    BIO is the largest trade association to serve and represent the biotechnology industry in the United States and around the globe.  Indeed, BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations.   BIO members are involved in the research and development of healthcare, agricultural, industrial, and environmental biotechnology products.  In Illinois BIO works in collaboration with iBIO, whose membership includes strong representation from the bio-pharmaceutical sector.  This sector accounts for a large portion of the $98 billion in biotech annual economic output and 369,000 directly and indirectly-created jobs in the state.  
January 31 2014
Dear Ms. Gibson: To Whom It May Concern: The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the Texas Health and Human Services Commission (HHSC) proposed rule regarding 340B program reimbursement (the “Proposed Rule”).  BIO is the largest trade association to serve and represent the biotechnology industry in the United States and around the globe.  Indeed, BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations.   BIO members are involved in the research and development of healthcare, agricultural, industrial, and environmental biotechnology products. 
January 21 2014
BIO's Senior Policy Consultant, Peter Pellerito, testified before the Michigan Legislature's Bioscience Caucus on economic development initiatives that support the growth of the bioscience industry.
May 8 2013
BIO  urges Florida Governor Scott to sign House Bill 365 – a bill related to the substitution of biologic and biosimilar medicines – which recently passed out of the Legislature.
February 1 2013
BIO supports passage of Florida House Bill 365, which provides requirements for pharmacist to dispense substitute biological products that are determined to be interchangeable for prescribed biological product.
July 11 2014
Today's oral arguments offered an important opportunity to educate stakeholders within Alameda County and all of California about the unnecessary and burdensome impacts that will result if this proposed take back program is allowed to stand.
May 29 2014
Delaware Governor Markell signed legislation designed to create a pathway for the substitution of interchangeable biologic medicines.
May 16 2014
BIO and Delaware Bio call upon Governor Markell to sign critical legislation to create a pathway for the substitution of interchangeable biologic medicines.
April 10 2014
BIO and Delaware Bio commend the Delaware State Senate for unanimously passing legislation yesterday designed to create a pathway for the substitution of interchangeable biologic medicines. 
April 9 2014
The House Subcommittee on Capital Markets and Government Sponsored Enterprises held a hearing titled “Legislative Proposals to Enhance Capital Formation for Small and Emerging Growth Companies.” Brian Hahn, Chief Financial Officer of GlycoMimetics, Inc. presented testimony at the hearing on enhancements to the capital markets that can increase access to investors and decrease unnecessary regulatory burdens for emerging biotech companies trading on the public market.